Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Michael Prugger & Thomas Berger. (2013) Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases. Patient Related Outcome Measures 4, pages 75-85.
Read now
Read now
Sheryl R. Haut, E. Jay Bienen & Aaron Miller. (2012) Clinical overview of the seizure risk of dalfampridine
. Expert Opinion on Drug Safety 11:4, pages 651-657.
Read now
Read now
Articles from other publishers (19)
Paula Schumann, Maria Scholz, Katrin Trentzsch, Thurid Jochim, Grzegorz Śliwiński, Hagen Malberg & Tjalf Ziemssen. (2022) Detection of Fall Risk in Multiple Sclerosis by Gait Analysis—An Innovative Approach Using Feature Selection Ensemble and Machine Learning Algorithms. Brain Sciences 12:11, pages 1477.
Crossref
Crossref
Giovanni Castelnovo, Oliver Gerlach, Mark S. Freedman, Arnfin Bergmann, Vladimiro Sinay, Tamara Castillo-Triviño, George Kong, Thijs Koster, Heather Williams, Arie R. Gafson & Joep Killestein. (2021) Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study. CNS Drugs 35:9, pages 1009-1022.
Crossref
Crossref
Maria Grazia Maggio, Daniele Tripoli, Bruno Porcari, Alfredo Manuli, Serena Filoni, Antonino Naro, Mareike Eschweiler & Rocco Salvatore Calabrò. (2021) How may patients with MS benefit from using music assisted therapy? A case-control feasability study investigating motor outcomes and beyond.. Multiple Sclerosis and Related Disorders 48, pages 102713.
Crossref
Crossref
Maria Scholz, Rocco Haase, Katrin Trentzsch, Marie Luise Weidemann & Tjalf Ziemssen. (2021) Fear of falling and falls in people with multiple sclerosis: A literature review. Multiple Sclerosis and Related Disorders 47, pages 102609.
Crossref
Crossref
Rocco Salvatore Calabrò, Margherita Russo, Antonino Naro, Rossella Ciurleo, Giangaetano D'Aleo, Carmela Rifici, Tina Balletta, Cristian La Via, Massimo Destro, Placido Bramanti & Edoardo Sessa. (2020) Nabiximols plus robotic assisted gait training in improving motor performances in people with Multiple Sclerosis.. Multiple Sclerosis and Related Disorders 43, pages 102177.
Crossref
Crossref
Anna Lubkowska, Aleksandra Radecka, Anna Knyszyńska & Joanna Łuczak. (2019) Effect of whole-body cryotherapy treatments on the functional state of patients with MS (multiple sclerosis) in a Timed 25-Foot Walk Test and Hand Grip Strength Test. Pomeranian Journal of Life Sciences 64:4, pages 46-49.
Crossref
Crossref
Jerry S. Wolinsky, Xavier Montalban, Stephen L. Hauser, Gavin Giovannoni, Patrick Vermersch, Corrado Bernasconi, Gurpreet Deol-Bhullar, Hideki Garren, Peter Chin, Shibeshih Belachew & Ludwig Kappos. (2018) Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology 84:4, pages 527-536.
Crossref
Crossref
Margherita Russo, Vincenzo Dattola, Maria C. De Cola, Anna L. Logiudice, Bruno Porcari, Antonino Cannavò, Francesca Sciarrone, Rosaria De Luca, Francesco Molonia, Edoardo Sessa, Placido Bramanti & Rocco S. Calabrò. (2018) The role of robotic gait training coupled with virtual reality in boosting the rehabilitative outcomes in patients with multiple sclerosis. International Journal of Rehabilitation Research 41:2, pages 166-172.
Crossref
Crossref
María Belén Marzal-Alfaro, María Luisa Martín Barbero, JoseM García Domínguez, Fernando Romero-Delgado, María Luisa Martínez Ginés, Ana Herranz & María Sanjurjo-Sáez. (2018) Impact of fampridine on quality of life: clinical benefit in real-world practice. European Journal of Hospital Pharmacy 25:3, pages 138-143.
Crossref
Crossref
Tjalf Ziemssen, Christine Prosser, Jennifer Scarlet Haas, Andrew Lee, Sebastian Braun, Pamela Landsman-Blumberg, Angela Kempel, Erika Gleißner, Sarita Patel & Ming-Yi Huang. (2017) Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment. BMC Neurology 17:1.
Crossref
Crossref
Gabriel Leonard, Yves Lapierre, Jen-Kai Chen, Rima Wardini, Joelle Crane & Alain Ptito. (2017) Noninvasive tongue stimulation combined with intensive cognitive and physical rehabilitation induces neuroplastic changes in patients with multiple sclerosis: A multimodal neuroimaging study. Multiple Sclerosis Journal - Experimental, Translational and Clinical 3:1, pages 205521731769056.
Crossref
Crossref
Björn Zörner, Linard Filli, Katja Reuter, Sandra Kapitza, Lilla Lörincz, Tabea Sutter, David Weller, Melinda Farkas, Christopher S Easthope, Adam Czaplinski, Michael Weller & Michael Linnebank. (2016) Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. Multiple Sclerosis Journal 22:11, pages 1463-1475.
Crossref
Crossref
Brian M. Sandroff, Rachel E. Klaren & Robert W. Motl. (2015) Relationships Among Physical Inactivity, Deconditioning, and Walking Impairment in Persons With Multiple Sclerosis. Journal of Neurologic Physical Therapy 39:2, pages 103-110.
Crossref
Crossref
Mitchell E Tyler, Kurt A Kaczmarek, Kathy L Rust, Alla M Subbotin, Kimberly L Skinner & Yuri P Danilov. (2014) Non-invasive neuromodulation to improve gait in chronic multiple sclerosis: a randomized double blind controlled pilot trial. Journal of NeuroEngineering and Rehabilitation 11:1.
Crossref
Crossref
Lara A. Pilutti, Deirdre Dlugonski, Brian M. Sandroff, Yoojin Suh, John H. Pula, Jacob J. Sosnoff & Robert W. Motl. (2013) Gait and six-minute walk performance in persons with multiple sclerosis. Journal of the Neurological Sciences 334:1-2, pages 72-76.
Crossref
Crossref
Meheroz H. Rabadi, Kimberly Kreymborg & Andrea S. Vincent. (2013) Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function. Drugs in R&D 13:3, pages 175-181.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2012) Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU. Drugs & Therapy Perspectives 28:12, pages 1-4.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2012) Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU. Drugs & Therapy Perspectives 28:12, pages 1-4.
Crossref
Crossref
Theodore E Pikoulas & Matthew A Fuller. (2012) Dalfampridine: A Medication to Improve Walking in Patients with Multiple Sclerosis. Annals of Pharmacotherapy 46:7-8, pages 1010-1015.
Crossref
Crossref